Emergency Use Protocol for EPI-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2016
At a glance
- Drugs Vatiquinone (Primary)
- Indications Mitochondrial disorders
- Focus Therapeutic Use
- Sponsors Edison Pharmaceuticals
- 18 Mar 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 18 Mar 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 12 Feb 2014 New trial record